Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial.
about
Profile of tofacitinib citrate and its potential in the treatment of moderate-to-severe chronic plaque psoriasisType I/II cytokines, JAKs, and new strategies for treating autoimmune diseasesEvaluating Dosage Optimality for Tofacitinib, an Oral Janus Kinase Inhibitor, in Plaque Psoriasis, and the Influence of Body WeightEffects of tofacitinib on lymphocyte sub-populations, CMV and EBV viral load in patients with plaque psoriasis.Efficacy and safety of secukinumab in the treatment of moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trialsTreatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a Phase 2b randomized clinical trial.[Rheumatoid arthritis].STAT2 is involved in the pathogenesis of psoriasis by promoting CXCL11 and CCL5 production by keratinocytes.Pregnancy Outcomes in the Tofacitinib Safety Databases for Rheumatoid Arthritis and Psoriasis.JAK inhibition using tofacitinib for inflammatory bowel disease treatment: a hub for multiple inflammatory cytokinesOral tofacitinib efficacy, safety and tolerability in Japanese patients with moderate to severe plaque psoriasis and psoriatic arthritis: A randomized, double-blind, phase 3 study.Effect of tofacitinib withdrawal and re-treatment on patient-reported outcomes: results from a Phase 3 study in patients with moderate to severe chronic plaque psoriasis.Quantitative Evaluations of Time-Course and Treatment Effects of Systemic Agents for Psoriasis: A Model-Based Meta-Analysis.A Review of Psoriasis, Therapies, and Suicide.Tofacitinib for the treatment of psoriasis.Managing Scalp Psoriasis: An Evidence-Based Review.Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis.Janus kinase (JAK) inhibitors for the treatment of skin and hair disorders: a review of literature.Tofacitinib for the treatment of moderate to severe chronic plaque psoriasis in Japanese patients: Subgroup analyses from a randomized, placebo-controlled phase 3 trial.Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study.Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.JAK inhibition as a therapeutic strategy for immune and inflammatory diseases.Tofacitinib: A New Oral Therapy for Psoriasis.JAK inhibition as a therapeutic strategy for immune and inflammatory diseases.Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial.Oral Tofacitinib for the Treatment of Adults with Moderate to Severe Chronic Plaque Psoriasis.Oral tofacitinib for psoriasis: what happens with interrupted treatment?
P2860
Q26765028-DCAE72EB-1000-4DE9-BA0B-1F18CD3E7E7FQ26775111-B4BE160A-00E6-409B-B0A2-80B34DB0BCBAQ33729774-722772B0-CD2E-4325-9CE1-CC495BA2DEC1Q35620368-90B93D0C-3888-4073-9D6C-42498A020D5FQ35643453-40E9EA26-ED06-4E3A-876B-5813CE2C7E06Q36157003-D9CA37EA-F4A0-4679-A15F-0A1A54735878Q36241682-D68A62D1-B20B-4312-A4AA-D566A073C0ABQ36363330-4BD3F2FE-DD6E-42AA-8ECD-D9AC6FE0AA3BQ37067150-A2E6A37C-4B86-4FAB-8ABE-3730DBD753A8Q37148745-8E0970B3-30D3-4A1A-ADD0-7A75E8F1497AQ37345488-53D63941-5649-4F83-8345-0E47F8B123D1Q37631750-55BBF99A-758D-47A4-B16B-277F571FE855Q38799023-B05DB841-569E-4314-ABE9-8A9C9291B165Q38840271-180974C9-7F5E-41D4-93BF-CFF062A69C52Q38856883-E25A74A6-9863-4B2B-9007-0DBCD86371AEQ38960080-13136A27-24B9-422E-A31B-2DBF07646CBCQ38965214-A558FC4E-08BE-4592-85CE-6F4A851C865DQ39055724-46791191-6E87-4FAF-9705-2266335DE2CDQ40132474-6C878645-5CA3-4F36-A53B-F9BE8BBDB07CQ47100492-D8B4B164-1104-4222-9247-F2087444C17AQ47260366-9881EF23-8578-4D85-9EAD-F3AF25B7EC5AQ47439880-9200BD76-002C-4D70-9CF0-51A27CB99B4BQ47623085-E8F648A7-5615-41E3-8B5A-4AB027270CF0Q48556502-56C60263-7210-4C64-84FF-2FA8114E1043Q51637913-579B8152-8ECF-4BCB-82FA-0D10E4984134Q54214722-01D6E81B-1933-42AE-BB15-5D86D1BBB7E0Q54272742-E0418ED9-54CC-4920-83A1-90AD4830EA56
P2860
Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh-hant
name
Tofacitinib withdrawal and ret ...... a randomized controlled trial.
@en
Tofacitinib withdrawal and ret ...... a randomized controlled trial.
@nl
type
label
Tofacitinib withdrawal and ret ...... a randomized controlled trial.
@en
Tofacitinib withdrawal and ret ...... a randomized controlled trial.
@nl
prefLabel
Tofacitinib withdrawal and ret ...... a randomized controlled trial.
@en
Tofacitinib withdrawal and ret ...... a randomized controlled trial.
@nl
P2093
P2860
P356
P1476
Tofacitinib withdrawal and ret ...... a randomized controlled trial.
@en
P2093
L Mallbris
M Bachinsky
R Bissonnette
P2860
P304
P356
10.1111/BJD.13551
P407
P577
2015-04-02T00:00:00Z